AST1306, A Novel Irreversible Inhibitor of the Epidermal Growth Factor Receptor 1 and 2, Exhibits Antitumor Activity Both In Vitro and In Vivo

A Single-Dose, Crossover, Placebo- and Moxifloxacin-Controlled Study to Assess the Effects of Neratinib (HKI-272) on Cardiac Repolarization in Healthy Adult Subjects

(2010) B. Hug et al.   CLINICAL CANCER RESEARCH

Personalizing Therapy in an Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor–Resistant Non–Small-Cell Lung Cancer Using PF-00299804 and Trastuzumab

(2010) Ronan J. Kelly et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors

(2010) Timothy A. Yap et al.   JOURNAL OF CLINICAL ONCOLOGY

Discovery and SAR of Thiazolidine-2,4-dione Analogues as Insulin-like Growth Factor-1 Receptor (IGF-1R) Inhibitors via Hierarchical Virtual Screening

(2010) Xiaofeng Liu et al.   JOURNAL OF MEDICINAL CHEMISTRY

Enhanced Anticancer Effect of the Combination of BIBW2992 and Thymidylate Synthase-Targeted Agents in Non-Small Cell Lung Cancer with the T790M Mutation of Epidermal Growth Factor Receptor

(2010) K. Takezawa et al.   MOLECULAR CANCER THERAPEUTICS

GA3, a new gambogic acid derivative, exhibits potent antitumor activities in vitro via apoptosis-involved mechanisms

(2009) Hua Xie et al.   ACTA PHARMACOLOGICA SINICA

A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer

(2008) D. Laheru et al.   CLINICAL CANCER RESEARCH

Naturally Occurring Homoisoflavonoids Function as Potent Protein Tyrosine Kinase Inhibitors by c-Src-Based High-Throughput Screening

(2008) Li-Gen Lin et al.   JOURNAL OF MEDICINAL CHEMISTRY

Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells

(2008) D. Zhang et al.   MOLECULAR CANCER THERAPEUTICS

The T790M "gatekeeper" mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor

(2008) N. Godin-Heymann et al.   MOLECULAR CANCER THERAPEUTICS

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

(2008) A. J. Gonzales et al.   MOLECULAR CANCER THERAPEUTICS

The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

(2008) C.-H. Yun et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA